Clinical Predictors of Acute Response With Olanzapine in Psychotic Mood Disorders
Carlos A. Zarate, Jr., Rajesh Narendran, Mauricio Tohen, Jim J. Greaney, Arielle Berman, Stephanie Pike, and Alex Madrid
J Clin Psychiatry 1998;59(1):24-28
© Copyright 2016 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: In controlled studies of patients
with schizophrenia, the atypical antipsychotic olanzapine has
been shown to be more effective in the treatment of positive and
negative symptoms compared with haloperidol at doses of 10
mg/day. However, little is known about the efficacy of olanzapine
in patients with psychotic mood disorders. The purpose of this
study was to assess the efficacy of olanzapine in the treatment
of these psychotic mood disorders in comparison with nonaffective
psychotic disorders and to identify clinical factors associated
with olanzapine response.
Method: In a naturalistic setting, by reviewing
medical records, we assessed response to olanzapine and factors
associated with response to olanzapine in 150 consecutive
patients newly treated with the drug at a nonprofit academic
psychiatric hospital.
Results: Patients displaying a
moderate-to-marked response to olanzapine were more likely to be
younger; be female; receive a diagnosis of bipolar disorder; and
have a shorter duration of illness, shorter length of stay prior
to olanzapine, and longer duration of trial.
Conclusion: Olanzapine may be a useful
alternative or adjunctive treatment for patients with bipolar
disorder.